Pneumocystis carinii contains a major group of antigens which migrates as a broad band of 45 to 55 kDa and 35 to 45 kDa in organisms derived from rats and humans, respectively. This complex is among the most common P. carinii antigens found in the respiratory tract and is recognized by serum antibodies of infected individuals. We have isolated a cDNA clone encoding the 3' portion of a 45-to 55-kDa antigen of rat-derived P. carinii. The predicted protein encoded by this cDNA contains a distinctive domain composed of 10 copies of a 7-amino-acid sequence motif rich in glutamic acid residues. Affinity-purified antibodies to this peptide reacted with the 45-to 55-kDa band of rat-derived P. carinii and with the 35-to 45-kDa band of human-derived P. carinii, indicating shared epitopes. The fusion protein was recognized by serum antibodies from rats and humans with natural exposure to P. carinii and by human immunodeficiency virus patients with P. carinii pneumonia. The production of this recombinant protein should allow more detailed studies of the host-parasite relationship of this important opportunistic infection.
Pneumocystis cannii is an important pulmonary pathogen of compromised hosts, but the immunobiology and pathogenesis of infection caused by this organism are poorly understood. In recent years, several important P. carinii antigens have been identified by Western blot (immunoblot) studies (15, 16, 21, 23, 37) . A glycoprotein antigen (gpl20) that displays an apparent molecular size of 120 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under reducing conditions appears to reside on the surface of the organism. This prominent moiety has epitopes that are cross-reactive between P. cannii isolated from humans, rats, mice, rabbits, and ferrets as well as species-specific epitopes. Another major class of antigens found in rodent-derived P. cannii migrates as a broad band in the 45-to 55-kDa range. In human-derived P. cannii, a similar intensely staining band of reactivity migrates between 35 and 45 kDa. It is the most common antigen found in the lungs and bronchoalveolar fluid of humans with P. carinii pneumonia (32, 37) .
Analysis of P. carinii antigens has been limited by the lack of a reliable culture system and other formidable technical problems. Infected lungs are the major source of organisms, but this material may be contaminated with host cells and other microbes. Biochemical purification has resulted in only small quantities of purified antigen (14, 25, 30) . Recombinant DNA techniques have led to the identification of several P. carinii genes (9, 11) , but until now no genes encoding P. carinii antigens had been isolated.
In the present study, we isolated a cDNA clone encoding a portion of an immunodominant 45-to 55-kDa antigen of rat-derived P. cannii. The predicted protein encoded by this cDNA contained a distinctive domain composed of 10 copies of a 7-amino-acid sequence motif rich in glutamic acid residues. The peptide produced by the expression of the cDNA in Eschenchia coli was recognized by sera from immune rats and from patients with P. carinii pneumonia.
* Corresponding author.
MATERIALS AND METHODS Microorganisms. P. carinii organisms were isolated from corticosteroid-treated Lewis rats by a method described previously (6, 7) . Briefly, the lungs of the sacrificed animal were harvested and homogenized in a Stomacher 80 blender (Tekmar Inc., Cincinnati, Ohio) and then filtered through sterile gauze. After centrifugation at 1,000 x g for 10 min at 4°C, the pellet was treated with 0.85% ammonium chloride for 10 min to lyse erythrocytes. The pellet was washed twice with phosphate-buffered saline solution (PBS), resuspended in PBS, and filtered several times through a 10-,um-pore-size Mitex filter to remove contaminating host lung cells. Aliquots of the homogenate were examined with Diff-Quick stain (American Scientific Products, McGaw Park, Ill.) for quantitation of the organisms and were then spread on Mueller-Hinton and Sabouraud dextrose agar plates for detection of bacterial and fungal contaminants. Specimens with no detectable bacterial or fungal contamination were stored at -70°C for later use. Human-derived P. carinii organisms, used as a source of antigen, were isolated from an autopsy lung sample from an AIDS patient by similar techniques.
Antibodies. Hyperimmune rabbit serum raised to SDSsolubilized rat-derived P. carinii (37) was used for screening the cDNA library and for initial characterization of resultant clones. The rabbit serum was rendered specific for P. carinii by adsorption with normal rat lung and sequential passage over columns containing albumin and E. coli XL-1 Blue lysate proteins immobilized by linkage of their amino groups to a coupling gel (Aminolink; Pierce, Rockford, Ill.). Hyperimmune rabbit serum raised to SDS-solubilized humanderived P. carinii isolated from an AIDS patient (37) was used following adsorption to desiccated fragments of normal human lung.
Monoclonal antibodies to rat-derived and human-derived P. cannii were raised in BALB/c mice by standard techniques (7, 24) . The antibodies were characterized by the apparent molecular weights of the antigens that they recognized and by the presence of cross-reactivity between rat-and human-derived antigens. The monoclonal antibodies demonstrated no reactivity to bacteria, fungi, or protozoa by Western blot or indirect fluorescent-antibody (IFA) assays.
Rat sera containing P. carinii-specific antibodies were obtained from three sources: (i) nonimmunosuppressed rats naturally exposed to P. carinii, (ii) immunosuppressed rats with P. carinii pneumonia, and (iii) rats that had developed pneumocystosis and had been allowed to recover following withdrawal of immunosuppression. Sera were also obtained from rats that were free ofP. carinii and had no detectable P. carinii-specific antibodies (39, 40) . Either these sera were used individually or specimens from five animals with antibodies to P. carinii were combined to form an "immune" rat serum pool. Human sera were obtained from normal healthy blood donors at the Hoxworth Blood Bank, Cincinnati, Ohio. Sera from human immunodeficiency virus (HIV)-infected individuals were obtained from the University of Cincinnati AIDS Related Disease Clinic. Random samples were obtained from CDC class II and III patients (five patients from each class) and from five CDC class IV patients who had not had any episodes of P. carinii pneumonia. Serum specimens from some patients were also combined to form pooled "immune" serum. In addition, multiple sequential samples of serum were examined from five additional CDC class IV patients, each with one or more episodes of P. carinii pneumonia (26) .
Polyclonal antibodies against the fusion protein were produced in a rabbit by using Titermax (CytRx, Norcross, Ga.) as an adjuvant. The rabbit was then boosted 4 weeks later and bled the following week. Polyclonal rabbit anti-fgalactosidase antibodies were obtained from 5-Prime, 3-Prime, West Chester, Pa.
SDS-PAGE, immunoblot, and IFA assays. SDS-PAGE and immunoblotting were performed as previously described (23, 37) . Preparative gels of partially purified fusion protein, 3-galactosidase (Sigma, St. Louis, Mo.), and rat-and human-derived P. carinii were electrophoresed and transferred to nitrocellulose. Strips cut from these blots were reacted with individual sera overnight at 4°C, washed extensively, and probed with goat anti-rat, anti-human, or anti-mouse immunoglobulin G (heavy-and light-chain specific). IFA was performed on P. carinii organisms that were heat or acetone fixed to Teflon-coated glass slides, as previously described (38) .
Nucleic acid isolation from P. carinii. Organisms from a single Lewis rat were isolated as described above. RNA was isolated from 1011 P. carinii organisms by the method of Chomczynski and Saechi (4) . The For pulsed-field gel electrophoresis (PFGE), P. carinii organisms were embedded in 0.6% low-gelling agarose (Sigma), and the embedded organisms were treated with proteinase K and sarcosyl to extract the DNA. PFGE was then performed by using conditions previously described (19) . P. carinii DNA and plasmid and phage DNA were extracted by standard methodologies (19, 31) .
cDNA library construction. Hemimethylated doublestranded cDNA was prepared from 4 ,ug of P. carinii mRNA by the RNase H method (Uni-ZAP; Stratagene) according to the manufacturer's instructions (17) . After the fill-in reaction, EcoRI linkers were added, followed by cleavage by XhoI, to facilitate directional cloning into lambda ZAPII. The cDNA was then ligated into the bacteriophage lambda ZAPII between the EcoRI and XhoI sites, packaged with Gigapack Gold Plus packaging extract (Stratagene), and plated on E. coli PLK-F' cells. The library was amplified and replated on E. coli XL-1 Blue cells for further screening.
E. coli strains XL-1, Sure, PLK-F', and HB101 were cultured in Luria-Bertani broth as needed.
Library screening and characterization of immunoreactive clones. By using standard procedures, the cDNA library was induced with isopropyl-13-D-thiogalactopyranoside (IPTG) and screened with polyclonal rabbit antiserum raised against rat-derived P. carinii. Immunoreactive clones were isolated, and phage DNA was prepared from each reactive clone. The insert for each of these clones was amplified by polymerase chain reaction (PCR) using primers within the polylinker of lambda ZAPII (primer 1, AGCTCCACCGCGGTGGCG; primer 2, TGGGTACCGGGCCCCCCC). Concurrently run controls included Bluescript plasmids with no insert or with an insert of known size. PCR products from the two classes of inserts identified were labeled with [at-32P]dCTP (New England Nuclear, Boston, Mass.) by random priming. These probes were hybridized to dot blots of phage DNA of all the immunoreactive clones under stringent conditions. One isolate from each class of immunoreactive clones was excised from lambda ZAPII by coinfection with helper phage R408 to yield Bluescript SK II(-) plasmid clones.
Plasmid subclones and expression of recombinant subclones in E. coli. Bluescript clones pSK599 and pSK790 were the source of all subsequent constructs. To ascertain if the fusion protein produced by pSK599 was the immunoreactive protein, a frameshift was created that altered the reading frame and resulted in the production of a 59-amino-acid peptide. The frameshift mutation was created as follows: pSK599 was digested with XbaI, blunt ended with the Klenow fragment of DNA polymerase, religated, and transformed into XL-1 Blue cells. Colonies were picked and plasmids were screened for the loss of the XbaI site.
To determine if the repeated domain was immunoreactive, a plasmid lacking the portions of the cDNA 5' or 3' to the repeat was constructed. The construct pSK599A316 was made as follows: pSK599 (which lacks the 5' portion of the cDNA) was linearized by digestion with EcoO109 at a site 3' to the XhoI site, partially digested with AvaIl (at a site 3' to the repeat within the cDNA [ and pSK790 by coinfection with helper phage R408.
Sequence of cloned cDNA. cDNA inserts pSK599 and pSK790 were both sequenced by modified double-strand sequencing (Fig. 1) . pSK599 contained the 3' portion of clone pSK790 from bases 191 to 790. The sequence displayed several features consistent with those expected of a P. carinii mRNA. A poly(A) tail was found that was related to a XhoI site in a manner consistent with the production of cDNA with a XhoI-poly(T) primer. A canonical polyadenylation signal (AAUAAA) was present 46 bp upstream of the poly(A) tail. The insert of pSK790 had a 695-nucleotide open reading frame (ORF) extending from the beginning of the insert to a stop codon at position 695. Eighty percent of the codons within the ORF had either A or T in the third position of the codon; a strong A or T bias has been noted in both of the previously sequenced protein-encoding genes of P. carinii (9, 11) . The ORF was predicted to encode a 225-aminoacid peptide with a molecular mass of 24,905 Da. The predicted peptide contained a repeated motif consisting of 10 copies of a 7-amino-acid sequence (Fig. 2) . Each copy was initiated by a proline residue and was extremely rich in glutamic acid residues. Some variability was seen among the repeated segments, but proline in position 1, threonine in position 2, and glutamic acid in position 4 were almost invariant.
Hybridization of cloned cDNA to P. carinii chromosomal and Northern (RNA) blots. To show that the cloned cDNA was represented within the genome of P. cannii, labeled cDNA was hybridized to a PFGE chromosomal blot of P.
carinii. Labeled insert cDNA from pSK790 hybridized strongly to a chromosome of 670 kb on a field inversion gel electrophoresis blot of rat-derived P. carinii DNA (Fig. 3) .
This probe showed no reactivity to rat DNA by dot blot analysis. To determine if the cloned cDNA was nearly full-length, labeled pSK790 was used to probe a Northern blot of P. carinii RNA. The cDNA hybridized to a single band of approximately 1.3 kb, indicating that the cDNA is a copy of the 3' end of a 1.3-kb mRNA (not shown). An mRNA of this size could encode a protein as large as 43 kDa.
Expression of fusion proteins. A fusion protein encoded by pSK599 was analyzed by immunoblotting to verify reactivity with the rabbit polyclonal antiserum used to screen the library. To produce fusion protein, a broth culture of E. coli XL-1 containing pSK599 was induced with IPTG. Immunoblots of the total protein lysate were probed with rabbit anti-rat-derived P. cannii antiserum. An immunoreactive band of about 28,000 Da was detected (not shown). This size was similar to that predicted for the peptide that would be produced from pSK599. To verify that the 28-kDa band represented the fusion protein produced by pSK599, a frameshift mutation was created in pSK599 that altered the translational reading frame such that a fusion protein of only 59 amino acids, 39 of which were from plasmid vector codons, was produced. The immunoreactive band of 28,000 Da could not be detected when this frameshift mutant was induced. The 28-kDa protein was not present in induced E. coli XL-1, XL-1 with Bluescript plasmid, or uninduced pSK599.
To determine if the repeated domain was immunoreactive, plasmid pSK599A316 was used. Plasmid pSK599A316 contained a truncated cDNA which would be predicted to produce a 20-kDa fusion protein that included residues 65 to 169 (Fig. 1) irrelevant insert, or uninduced pUR/SK599. Fusion protein 1-Gal/599, partially purified from inclusion granules within induced E. coli, was recognized by the rabbit anti-ratderived P. carinii antiserum used to detect the reactive cDNA clone but not by rabbit antiserum to human-derived P. carinii (Fig. 4, lanes 1 and 2) . However, the fusion protein was recognized by pooled immune serum specimens from both rats and humans (Fig. 4, lanes 3 and 4) . These sera demonstrated no reactivity to ,-galactosidase immunoblotted under identical conditions. Sera from rats with no exposure to P. carinii and no demonstrable anti-P. carinii antibodies did not react with the J-Gal/599 fusion protein.
Monoclonal antibodies to the P. carinii gpl20 antigen also did not detect the ,-Gal/599 fusion protein.
Affinity nized a band of approximately 35 kDa on immunoblots of human-derived P. carinii (Fig. 5, lane 5) . Polyclonal antibodies raised to the fusion protein 3-Gal/599 reacted with bands similar to those recognized by the eluted antibodies on immunoblots of both human-and rat-derived P. carinii.
To determine the location of the antigen on P. carinii, the eluted antibodies were reacted with whole P. carinni organisms by the IFA technique. No fluorescent staining occurred, suggesting either that the antigen is not a component of the outer cell wall or that its epitopes are not accessible.
Recognition of a 13-Gal/599 fulsion protein by a panel of rat and human sera. To determine the frequency with which epitopes within the I-Gal/599 fusion protein were recognized by rat and human antibodies, preparative SDS-polyacrylamide gels containing ,-Gal/599 fusion protein, ,B-galactosidase, or P. carinii lysate were immunoblotted to nitrocellulose, which was then cut into strips and reacted with the sera of interest. These results are summarized in Table 1 .
In the rat study, sera from 20 rats with antibodies to the 120-kDa and 45-to 55-kDa antigens of rat-derived P. cannii were screened for reactivity against the P-Gal/599 fusion protein and P-galactosidase. Serum from 18 of the 20 rats reacted avidly with the P-Gal/599 fusion protein but did not react with ,-galactosidase. Some reactivity was seen to lower-molecular-weight bands with both the ,-Gal/599 fusion protein and 3-galactosidase preparations, but no correlation was noted between these bands and the reactivity with the intact fusion protein. Sera from four rats were sampled when the rats arrived at our facility, at which time the sera exhibited no anti-P. cannii antibodies, and again after the rats had recovered from an episode of P. cannii pneumonia induced by immunosuppression (39, 40) . These animals all developed antibody responses to rat-derived P. cannii and to the ,-Gal/599 fusion protein, but they demonstrated no change in their antibody response to 1-galactosidase (Fig. 6) .
In the human study, sera from 20 healthy blood donors were tested in parallel against human-derived P. carinii, rat-derived P. cannii, 1-Gal/599 fusion protein, and 1-galac- tosidase by Western blotting. Sera from 18 of 20 individuals contained antibodies to human-derived P. carinii, while 13 of these 18 recognized rat-derived material. Of these 13, 10 recognized the 45-to 55-kDa antigen of rat-derived P. carinii, while the remainder recognized only higher-molecular-weight antigens. Antibodies reacting with the ,-Gal/599 fusion protein were found in 6 of the 10 serum specimens that reacted with the 45-to 55-kDa antigen of rat-derived P. carinii but in none of the sera from other individuals. None of these sera demonstrated reactivity with intact P-galactosidase.
Sera from randomly selected CDC class II, class III, or class IV HIV-infected patients were also studied (Table 1) . Of 10 class II or III patients, 7 demonstrated reactivity to rat-derived P. carinii and 6 had antibodies to human-derived organisms. None of these patients demonstrated reactivity to either the P-Gal/599 fusion protein or ,B-galactosidase. Teen CDC class IV HIV-infected patients were studied. Of five patients with no prior P. carinii pneumonia, three had antibodies to rat-and human-derived P. carinii. Reactivity with the 1-Gal/599 fusion protein was detected in two of these three individuals. Five of the class IV patients had suffered multiple episodes of pneumocystosis. These pa- tients all had detectable antibodies to both human-and rat-derived P. carinii. Three of these patients demonstrated reactivity to the ,B-Gal/599 fusion protein. None of the class IV patients had antibodies to 13-galactosidase.
Among the CDC class IV patients with multiple episodes of pneumocystosis, the presence of antibodies to the ,8-Gal/ 599 fusion protein varied with time (Fig. 7) . For one patient, antibodies were detected in all specimens and did not appear to change with episodes of P. carinii pneumonia. A second patient developed antibodies to the fusion protein associated with a third episode of P. carinii pneumonia. During this same period, the patient had antibodies against humanderived P. carinii in all serum specimens but had developed antibodies to rat-derived P. carinii only at the time of the third episode of pneumonia. Another patient had antibodies to both human-and rat-derived P. carinii and to the fusion protein; these antibodies diminished with the progression of his disease despite repeated episodes of P. carinii pneumonia.
DISCUSSION
The immune response to P. carindi has been studied extensively (15, 16, 18, 21, 23, 25, 37, 39, 40) P. carinii antigen has yet been purified and structurally characterized. Most studies of P. carinii antigens have focused on a high-molecular-weight complex (gpl20) which has been found in organisms obtained from rats, mice, ferrets, rabbits, and humans (15, 16, 21, 23, 37) . The gpl20 antigen, which migrates as a prominent discrete band on SDS-polyacrylamide gels and immunoblots, resides on the surface of P. carinii and is highly susceptible to proteolytic (13, 28, 29) .
Another major class of antigens appears as a broad band of 45 to 55 kDa in rat-derived P. carinii and of 35 to 45 kDa in human-derived P. carinii. Although prominent on immunoblots, these antigens stain poorly with protein stains on SDS-polyacrylhimide gels, suggesting the presence of a high carbohydrate or lipid content. The relationship of the 45-to 55-kDa antigen of rat-derived P. carinii to the 35-to 45-kDa P. carinii antigen, or that of these two antigens to gpl20, is poorly understood. The 45-to 55-kDa band is the earliest antigen and among the most prominent of those found in the respiratory tract of infected rats (20) , and the 35-to 45-kDa band is the most common antigen found in the lungs and bronchoalveolar lavage fluid of patients with pneumocystosis (32, 37) .
We used expression cloning to isolate the 3' portion of a cDNA encoding an antigen of rat-derived P. carinii which appears to be from the 45-to 55-kDa class. Antibodies affinity purified by absorption to a ,B-Gal/P. carinii fusion protein bound exclusively to material in the 45-to 55-kDa region of rat-derived P. carinii on an immunoblot, and the reaction could be blocked by prior incubation of the antibodies with the ,B-Gal/599 fusion protein. (27) . Numbers at left are molecular mass markers (in kilodaltons).
persist for a longer period of time (5, 40) . The present study has shown that 90% of rats with serum antibodies to P.
carinii recognize the 1-Gal/599 fusion protein. Although detailed analysis was not performed, the temporal relationship of antibody development to the P-Gal/599 fusion protein was similar to that of the 45-to 55-kDa antigen. The reactivity to the 1-Gal/599 fusion protein was not due to the presence of antibodies directed against the ,B-galactosidase moiety. Antibodies to intact ,B-galactosidase were not detected, and reactivity to lower-molecular-weight bands remained constant in sequentially studied sera whereas changes in reactivity to the fusion protein were evident. The incidence of anti-,B-galactosidase antibodies has previously been found to be highly variable, and the low incidence detected in this study is similar to results of earlier reports (8, 27) .
Seroepidemiological surveys have shown that the 35-to 45-kDa human-derived P. carinii antigen is the most frequently recognized antigen among normal and immunocompromised humans (26) . Given the evidence that epitopes on the 45-to 55-kDa antigen of rat-derived P. carinii are present on the 35-to 45-kDa antigen of human-derived P. carinii, human sera might be expected to recognize the ,B-Gal/599 fusion. Antibodies to the ,8-Gal/599 fusion protein were detected in a number of human serum specimens from both healthy and HIV-infected individuals. The frequency and pattern of human antibodies to the ,B-Gal/599 peptide were variable. The significance of the variability is not known and will require further study to resolve. Nevertheless, the data clearly showed that humans mount antibody responses to ,B-Gal/599.
From its amino acid sequence, the recombinant antigen was predicted to have multiple proteolytic cleavage sites, VOL. 60, 1992 on October 29, 2017 by guest http://iai.asm.org/ Downloaded from but previous studies indicated that the broad 45-to 55-kDa antigen band in whole P. carinii organisms is resistant to proteolytic degradation (23) . This might mean that the protein is not fully exposed on the surface of the organism or that there is more than one protein in the 45-to 55-kDa region. There appears to be no relationship between the recombinant antigen and the P. caninii gpl20 antigen, because antibodies affinity purified from the fusion protein did not react with the gpl20 antigen. In addition, monoclonal antibodies reactive with gp120 did not recognize the fusion protein.
The peptide encoded by the cloned cDNA was found to have an unusual amino acid sequence characterized by a repeated domain rich in glutamic acid residues. Comparison of this sequence with GenBank sequences detected no significant similarity with any known sequenced protein.
Glutamic acid-rich proteins from Plasmodium spp. have been reported, but their repeated domains do not appear to be similar to that detected here (8, 36) . Computer modeling of the secondary structure of our fusion protein (data not shown) predicted that the repeat would form two turns of an aL-helix, while the proline residues initiating each repeat would result in a 20 to 300 angulation between each ox-helix. A short hydrophobic domain at the carboxyl terminus of the peptide might represent a membrane anchor.
In many organisms, amino acid repeats are found within the products of structural genes (e.g., the merozoite surface antigen of Plasmodium falciparum), within enzymes (e.g., RNA polymerase II), and within housekeeping proteins (e.g., Plasmodium falciparum heat shock protein 70) (1, 3, 22, 33) . These repeated domains do not disrupt the function of these molecules. To our knowledge, similar repeated domains within proteins of fungal origin have rarely been reported (1). This is of note, given the recent evidence that P. carinii may be a fungus (10, 35, 41) . The recombinant fusion protein with this repeated domain is highly immunoreactive. In plasmodia, highly variable, immunodominant repeated regions of antigens are thought to divert the host immune response from critical antigenic targets (12) .
The isolation of this cDNA and the resulting production of a recombinant P. carinii antigen in pure form has allowed more detailed study of a P. caninii antigen and the host immune response in P. carinii infection. An important outcome of this work was the demonstration of epitopes shared by rat-derived and human-derived P. carinii. It should be possible to use the rat-derived P. carinii cDNA as a probe to clone the human analog of this gene and, through analysis of the gene sequence, to determine the basis for the difference in rat-and human-derived P. carinii forms of the antigen. The recombinant protein will serve as a pure antigen for the development of more specific humoral and cellular immune response assays and for the production of monoclonal and monospecific polyclonal antisera. Such reagents should be useful in refining the serology of P. carinii for application in studies on the epidemiology, diagnosis, and treatment of pneumocystosis.
